Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Data sourced from

and

Download Data

Freeline Therapeutics Holdings Plc Ending Cash for the quarter ending September 30, 2023: USD 29.45 M

Freeline Therapeutics Holdings Plc Ending Cash is USD 29.45 M for the quarter ending September 30, 2023, a -56.08% change year over year. Ending Cash is the amount of cash held by a company at the end of a specific period.

Freeline Therapeutics Holdings Plc Ending Cash for the quarter ending September 30, 2022 was USD 67.06 M, a -51.34% change year over year.
Freeline Therapeutics Holdings Plc Ending Cash for the quarter ending September 30, 2021 was USD 137.81 M, a -45.37% change year over year.
Freeline Therapeutics Holdings Plc Ending Cash for the quarter ending September 30, 2020 was USD 252.28 M, a 1,253.21% change year over year.
Freeline Therapeutics Holdings Plc Ending Cash for the quarter ending March 31, 2019 was USD 18.64 M, a 356.37% change year over year.

NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO	Mr. Michael J. Parini J.D.
IPO Date	Aug. 7, 2020
Location	United Kingdom
Headquarters	Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Key trends